Universal HBV vaccination programme with antenatal HBsAg screening cost saving in Israel

2021 ◽  
Vol 892 (1) ◽  
pp. 28-28
Keyword(s):  
Cost Saving ◽  
Vaccination Programme ◽  
Hbv Vaccination ◽  
Screening Cost ◽  
Hbsag Screening

scholarly journals Cost-effectiveness of paediatric influenza vaccination in the Netherlands

2020 ◽  
Author(s):  
Pieter T. de Boer ◽  
Franklin C.K. Dolk ◽  
Lisa Nagy ◽  
Jan C. Wilschut ◽  
Richard Pitman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Influenza Vaccination ◽  
Vaccination Programme ◽  
Risk Groups ◽  
Inactivated Vaccine ◽  
Vaccination Strategies ◽  
Clinical Risk ◽  
Vaccine Type ◽  
Clinical Risk Groups

AbstractBackgroundThis study evaluates the cost-effectiveness of extending the Dutch influenza vaccination programme for elderly and clinical risk groups to include paediatric influenza vaccination, taking indirect protection into account.MethodsAn age-structured dynamic transmission model was used that was calibrated to influenza-associated GP visits over four seasons (2010/11 to 2013/14). The clinical and economic impact of different paediatric vaccination strategies were compared over 20 years, varying the targeted age range, the vaccine type for children and the vaccine type for elderly and clinical risk groups. Outcome measures include averted symptomatic infections and deaths, societal costs and quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, and net health benefits (NHBs), using a willingness-to-pay threshold of €20,000 per QALY gained.ResultsAt an assumed coverage of 50%, adding vaccination of 2- to 17-year-olds with quadrivalent-live-attenuated influenza vaccine (Q-LAIV) to the current influenza vaccination programme was estimated to avert on average 406,270 symptomatic cases and 83 deaths per season compared to vaccination of elderly and risk groups with trivalent inactivated vaccine (TIV), and was cost-saving (cumulative 20-year savings of 36,396 QALYs and €1,680 million; NHB: 120,411 QALYs). This strategy dominated paediatric vaccination strategies targeting 2- to 6-year-olds or 2- to 12-year-olds, or paediatric vaccination strategies with TIV. The highest NHB was obtained when 2- to 17-year-olds were vaccinated with Q-LAIV and existing target groups switched from TIV to quadrivalent inactivated vaccine (NHB: 132,907 QALYs).ConclusionModelling indicates that paediatric influenza vaccination reduces the disease burden of influenza substantially and is cost-saving.

scholarly journals Modelling the hepatitis B vaccination programme in prisons

2005 ◽  
Vol 134 (2) ◽  
pp. 231-242 ◽  
Author(s):  
A. J. SUTTON ◽  
N. J. GAY ◽  
W. J. EDMUNDS ◽  
N. J. ANDREWS ◽  
V. D. HOPE ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Vaccination Coverage ◽  
Vaccination Programme ◽  
Drug Users ◽  
Hepatitis B Vaccination ◽  
England And Wales ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
Increased Risk ◽  
Potential Impact

A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. Over the coming years it is anticipated this vaccination programme will be extended. A model has been developed to assess the potential impact of the programme on the vaccination coverage of prisoners, ex-prisoners, and injecting drug users (IDUs). Under a range of coverage scenarios, the model predicts the change over time in the vaccination status of new entrants to prison, current prisoners and IDUs in the community. The model predicts that at baseline in 2012 57% of the IDU population will be vaccinated with up to 72% being vaccinated depending on the vaccination scenario implemented. These results are sensitive to the size of the IDU population in England and Wales and the average time served by an IDU during each prison visit. IDUs that do not receive HBV vaccine in the community are at increased risk from HBV infection. The HBV vaccination programme in prisons is an effective way of vaccinating this hard-to-reach population although vaccination coverage on prison reception must be increased to achieve this.

scholarly journals Twenty years of universal vaccination against hepatitis B in Italy: achievements and challanges

2012 ◽  
Vol 1 (2) ◽  
pp. 18 ◽  
Author(s):  
Luisa Romano' ◽  
Sara Paladini ◽  
Alessandro R. Zanetti
Keyword(s):  
Hepatitis B ◽  
Vaccination Programme ◽  
Risk Groups ◽  
Global Scale ◽  
Universal Vaccination ◽  
Hbv Vaccination ◽  
Hbsag Carriers ◽  
Substantial Progress ◽  
Mandatory Vaccination ◽  
And Control

Viral hepatitis B is a vaccine-preventable disease. Vaccination has proved to be safe and highly effective in reducing the incidence, the carrier rate and HBV-related mortality on a global scale. In Italy, universal vaccination against hepatitis B started in 1991 in infants as well as in adolescents, providing an outstanding record of safety and effectiveness. Within a few years, over 95% coverage was consistently reported. Today, some 17 million people are immune against hepatitis B and their immunity has been shown to be long-lasting. At present, no booster is required in healthy vaccinated people to sustain protection. Surveillance data from Italy have shown a clear overall decline in hepatitis B among successfully vaccinated individuals. Furthermore, a generation of children and young people (at present cohorts ranging from 0 to 32 years) is emerging with practically no markers of HBV infection. Italy’s vaccination programme has resulted in substantial progress being made towards the prevention and control of hepatitis B. The vaccination programme must continue. Maintaining mandatory vaccination of infants and increasing HBV vaccination coverage in high-risk groups, including households of HBsAg carriers as well as immigrants, remain a priority for the future.

scholarly journals Evaluation of the Hepatitis B Vaccination Programme in Medical Students in a Dutch University Hospital

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 69
Author(s):  
Leanne P. M. van Leeuwen ◽  
Laura Doornekamp ◽  
Simone Goeijenbier ◽  
Wesley de Jong ◽  
Herbert J. de Jager ◽  
...  
Keyword(s):  
Medical Students ◽  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Surface Antigen ◽  
Booster Vaccination ◽  
University Hospital ◽  
Hepatitis B Vaccination ◽  
Hbv Vaccination ◽  
Increased Risk ◽  
Primary Presentation

Healthcare workers (HCW) are at increased risk of contracting hepatitis B virus (HBV) and are, therefore, vaccinated pre-exposure. In this study, the HBV vaccination programme for medical students in a university hospital in the Netherlands was evaluated. In the first part, the effectiveness of the programme, which consisted of a vaccination with Engerix-B® at 0, 1, and 6 months, was retrospectively evaluated over 7 years (2012–2019). In the second part of this study, we followed students (the 2019 cohort) who had previously been vaccinated against HBV vaccination (4–262 months prior to primary presentation) in order to investigate the most efficient strategy to obtain an adequate anti hepatitis B surface antigen titre. In the latter, titre determination was performed directly during primary presentation instead of giving previously vaccinated students a booster vaccination first. The vaccination programme, as evaluated in the retrospective first part of the study, was effective (surpassed the protection limit of 10 IU/L) in 98.8 percent of the students (95% CI (98.4–99.2)). In the second part of our study, we found that 80 percent (95% CI (70–87)) of the students who had previously been vaccinated against HBV were still sufficiently protected and did not require a booster vaccination. With this strategy, the previously vaccinated students needed an average of 1.4 appointments instead of the 2 appointments needed with the former strategy. This knowledge is important and can save time and resources in the process of occupational HBV vaccination of HCW.

Sign in / Sign up

Export Citation Format

Share Document